Madrigal Pharmaceuticals is a biotechnology company dedicated to developing innovative therapies for liver diseases, particularly Non-Alcoholic Steatohepatitis (NASH). The company's primary product candidate, Resmetirom, aims to address significant unmet needs in the treatment of liver conditions. Madrigal collaborates with healthcare professionals and researchers to advance its understanding of liver disease and optimize clinical development strategies. Committed to patient safety and scientific rigor, Madrigal emphasizes a culture of compliance and quality in its clinical trials. The company's mission reflects a deep commitment to improving patient outcomes through rigorous research, collaboration, and ethical conduct, ensuring the best possible standards in drug development for the benefit of those affected by liver diseases.